Capsigen

Capsigen is discovering novel adeno-associated viruses (AAVs) to deliver gene therapies.- AAVs are designed to deliver genetic therapeutic payloads to cells when injected into a host. Capsigen is engineering custom AAVs to deliver medicine to target cells while avoiding entry into non-targeted cells. These AAV vectors are identified through Capsigen’s proprietary messenger RNA screening platform called TRADETM. The platform screens capsids to identify those with enhanced potency, specificity and speed. Data from the platform is incorporated into Capsigen’s data science platform to provide new insights into structure-function relationships that enable AAV capsids to be made, such as their neurotropic capsid, that can transduce neurons with high specificity.

Jobs: